| 18th week of 2010 patent applcation highlights part 47 |
| Patent application number | Title | Published |
|---|
| 20100112017 | Composition For The Preparation of Cosmetics, Cosmetic, and Method For the Preparation Of Water-Containing Cosmetics - Composition for the preparation of cosmetics comprising a mixture of (a) a polyoxyalkylene-modified diorganopolysiloxane of the formula: (A(R | 2010-05-06 |
| 20100112018 | Microcapsule, structure having a microcapsule, article having a microcapsule, and method of preparing microcapsules - A microcapsule, a structure including a microcapsule, an article including a microcapsule and a method of preparing microcapsules provided, the microcapsule includes at least one material selected from the group consisting of a magnetic substance, a dielectric substance and a combination thereof. The microcapsule also includes a volatile material. | 2010-05-06 |
| 20100112019 | METHOD FOR MAKING UP KERATINOUS SUBSTANCES AND KIT FOR THE IMPLEMENTATION OF SUCH A METHOD - A method for making up a support includes application to the support of at least (a) magnetic substances exhibiting a non-zero magnetic susceptibility, (b) one or more compounds X, (c) one of more compounds Y, with at least one of the compounds X and Y being a silicone compound and the compounds Y and X being capable of reacting together by a hydro silylation reaction in the presence of a catalyst, when they are brought into contact with one another, and (d) at least one catalyst. Application of (a), (b), (c) and (d) may be simultaneous or sequential in any order. Exposure to a magnetic field of at least a portion of the magnetic substances takes place before the interaction between the compounds X and Y is complete. | 2010-05-06 |
| 20100112020 | NANOFIBROUS STRUCTURES AND THEIR USE IN DENTAL APPLICATIONS - An electrospinning device is described for producing nanofibrous porous structures. The device comprises three or more neighbouring outlets ( | 2010-05-06 |
| 20100112021 | SUSTAINED-RELEASE COMPOSITION - A composition which comprises (A) a plurality of cross-linked polymer particles, said polymer being the polymerization product of at least two monomer units selected from the group consisting of monoalkenyl aromatic compounds, alkyl esters derived from a saturated alcohol and acrylic or methacrylic acid, and vinyl esters of an aliphatic carboxylic acid; and said cross-line polymer particles being loaded with (B) an active ingredient, the weight ratio of the active ingredient (B) to the polymer particles (A) being from 0.05 to 50:1, is useful to release the active ingredient over an extended period of time while controlling sebum on skin and hair. | 2010-05-06 |
| 20100112022 | Antiperspirant Products and Methods of Merchandising the Same - A method of merchandising an antiperspirant product, comprising the steps of offering a solid or cream antiperspirant product for sale, wherein the antiperspirant product is a water-in-oil emulsion comprising 5% or more of water and one or more plant-derived materials in the continuous oil phase and communicating to perspective buyers that the antiperspirant product is natural and/or provides an environmental benefit. | 2010-05-06 |
| 20100112023 | SILICONE MICROPARTICLES COMPRISING SILICONE ELASTOMER SPHERICAL MICROPARTICLES COATED WITH POLYORGANOSILSESQUIOXANE, AND METHOD OF PRODUCING SAME - Provided are silicone microparticles including 100 parts by mass of silicone elastomer spherical microparticles having a volume average particle diameter within a range from 0.1 to 100 μm, and 0.5 to 25 parts by mass of a polyorganosilsesquioxane that coats the surface of the silicone elastomer spherical microparticles, in which the silicone elastomer is capable of absorbing not less than 30 parts by mass of at least one oily substance selected from the group consisting of sebum, hydrocarbon oils and ester oils per 100 parts by mass of the silicone elastomer. These silicone microparticles are capable of absorbing a large amount of the above oily substances, are able to ameliorate various problems caused by sebum such as changes in cosmetic make-up properties, changes in the color of cosmetic materials and increased shininess of cosmetic materials, and are also able to suppress the greasiness, stickiness, and oily film feeling of cosmetic materials containing at least one of liquid oils composed of hydrocarbon oils and ester oils. The silicone microparticles can be produced by hydrolyzing and condensing an organotrialkoxysilane in a water medium, in the presence of the above silicone elastomer spherical microparticles and an alkaline material, thereby coating the surface of the silicone elastomer spherical microparticles with a polyorganosilsesquioxane. | 2010-05-06 |
| 20100112024 | TITANIUM DIOXIDE COATINGS HAVING ROUGHENED SURFACES AND METHODS OF FORMING TITANIUM DIOXIDE COATINGS HAVING ROUGHENED SURFACES - Methods for forming surface roughened titanium dioxide coatings are disclosed. Sol-gel compositions may be prepared having colloidal metal oxide particles and/or colloidal silica particles, formed on a substrate, and subsequently the coated substrate may be heated at a temperature sufficient to form a surface roughened anatase titanium dioxide coating. Surface roughened titanium dioxide coatings having at least one of improved antimicrobial properties, self-cleaning properties, hydrophilicity, and/or activation time are also disclosed. Substrates comprising such coatings are also disclosed. | 2010-05-06 |
| 20100112025 | Scented oil for application to a hunter's body - A composition for reducing or eliminating the exudation of human skin cells for inhibiting the scent of a human body from being detected by wildlife is produced by soaking at least three scented wafers each imitating a light natural fragrance in a container filled with generic mineral oil for a given time period with the scented wafers selected from a number of natural fragrances and the wafers are left soaking in the mineral oil until their scent sufficiently disperses throughout and permeates the mineral oil whereupon the oil suffused with the scent is poured into a smaller container such as spray bottle whereupon the individual sprays the mineral oil with the infused scent on his or her body prior to entering a wilderness area so that the individual's scent will be inhibited and reduced thereby allowing the individual to more closely approach undetected the wildlife for hunting, photography, or observation purposes. | 2010-05-06 |
| 20100112026 | SURFACES, METHODS AND DEVICES EMPLOYING CELL ROLLING - In various aspects, the present invention provides surfaces and materials for cell rolling applications, methods of making such surfaces and materials, and devices having such surfaces and materials. In some embodiments, the present invention provides surfaces with at least partial coatings of an ordered layer of cell adhesion molecules, or fragments, analogs, or modifications thereof, covalently bound to the surface of the substrate through an immobilization moiety. In some embodiments, the layer of a cell adhesion molecules further comprises a cell modifying ligand that can be targeted, e.g., to one or more specific cell types. | 2010-05-06 |
| 20100112028 | Composite material for use as protein carrier - The present invention relates to a material having osteoinductive and osteoconductive properties in vivo comprising a ceramic carrier, preferably containing calcium phosphate, and an active agent, preferably an osteoinductive protein/peptide or a drug, and a polymer, wherein the active agent is homogeneously coated on the carrier and within the polymer, which is preferably a degradable polymer. Said polymer modulates the release kinetic of the active agent and protects same from degradation to prolong the half-life in vivo. Moreover, the present invention relates to a method for the production of a material having osteoinductive and osteoconductive properties in vivo. | 2010-05-06 |
| 20100112029 | COMPOSITIONS AND METHODS FOR NUCLEUS PULPOSUS REGENERATION - Compositions for nucleus pulposus regeneration is provided. Such composition may comprise a scaffolding material and a pore creating agent dispersed within the scaffolding material. The pore creating agent is removed from the scaffolding material in vivo, after the composition is administered to a patient. The pore creating agent may include an active agent, such as a growth factor, which may be released as the pore creating agent is being gradually removed from the scaffolding material. In addition, removal of the pore creating agent results in a porous scaffold for cells capable of regeneration of nucleus pulposus, either existing in situ or delivered separately, to attach to for further proliferation and regeneration. | 2010-05-06 |
| 20100112030 | ROLE OF HEDGEHOG SIGNALING IN ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE - The present invention provides methods and related compositions for treating or preventing cardiovascular diseases, including, e.g., atherosclerosis, using an oxysterol. In addition, the present invention provides novel methods and related compositions for treating or preventing cardiovascular diseases, including, e.g., atherosclerosis, using a hedgehog protein, or a biologically active fragment or variant thereof. | 2010-05-06 |
| 20100112031 | Compositions And Methods For Regulating Extracellular Matrix Production In Adipose Derived Cells - The present application provides compositions and methods for regulating ECM production in ASCs and for isolating and using the various ECM molecules. The present application further provides methods for inducing various growth factors, cytokines and stem cell markers. | 2010-05-06 |
| 20100112032 | Bone/Polyurethane Composites and Methods Thereof - Present inventions present composites of bone particles and polyurethane(s), as well as methods of making such composite and uses thereof. A porous composite comprises a plurality of bone particles; and polyurethanes with which the bone particles are combined. To prepare a porous composite, a composition comprise a plurality of bone particles, polyurethane precursors including polyisocyanate prepolymers and polyols, water and catalyst. A composition is either naturally moldable and/or injectable, or it can be made moldable and/or injectable. After implantation or injection, a composition may be set to form a porous composite that provides mechanical strength and supports the in-growth of cells. Inventive composites have the advantage of being able to fill irregularly shape implantation site while at the same time being settable to provide the mechanical strength for most orthopedic applications. | 2010-05-06 |
| 20100112033 | STENTS COATED WITH NO- AND S-NITROSOTHIOL-ELUTING HYDROPHLIC POLYMERIC BLENDS - This invention relates to stents coated with hydrophilic polymers containing S-nitrosothiols, which are able to provide local delivery of both nitric oxide and S-nitrosothiols by diffusion. This device is intended for coronary angioplasty applications with the purpose of inhibiting acute and chronic restenosis and refers to processes of stent coating with hydrophilic polymers containing incorporated S-nitrosothiols. This invention refers to an intracoronary implant device used in medical procedures, and introduces new S nitrosothiol-eluting stents coated with hydrophilic polymer multilayers. The hydrophilic polymers used for coating are polyvinyl alcohol, polyvinylpirrolidone and polyvinyl alcohol/polyvinylpirrolidone, polyvinyl alcohol/polyethylene glycol, polyvinylpirrolidone/polyethylene glycol and polyvinyl alcohol/polyvinylpirrolidone/polyethylene glycol blends. The S-nitrosothiols incorporated to the polymer coatings are mainly primary S-nitrosothiols, characterized by the fact of the nitric oxide (NO) molecule being covalently bound to a sulfur (S) atom which, in turn, is linked to a primary carbon in the molecule's structure, thus constituting the S—NO chemical group. The coating processes include immersion of the stents in polymer solutions containing S-nitrosothiols and nebulization processes of the polymer solutions containing S-nitrosothiols onto the stent surface. | 2010-05-06 |
| 20100112034 | DRUG DEPOT WITH ANCHOR - A drug depot implantable at or near a target tissue site beneath the skin of a patient is provided, the drug depot comprising a therapeutically effective amount of a drug; at least one line having a distal end and a proximal end, the proximal end of the line attached to the drug depot; an anchor attached to the distal end of the line and configured to limit movement of the drug depot at or near the target tissue site, wherein the drug depot is capable of releasing the therapeutically effective amount of the drug over a period of at least one day. In some embodiments, the drug depot provided can include an effective amount of at least analgesic and/or at least one anti-inflammatory agent at or near a target site, and can reduce, prevent or treat inflammation and/or pain. | 2010-05-06 |
| 20100112035 | MULTIPLE COMPONENT FOOD PRODUCT USEFUL FOR DELIVERING GLUCOSAMINE AND/OR N-ACETYL-D-GLUCOSAMINE - Food products containing at least two components are provided. These products have at least one baked component and at least one non-baked component. The non-baked component contains either GLCN and/or NAG. | 2010-05-06 |
| 20100112036 | Cyanoacrylate-based liquid microbial sealant drape - The invention relates to methods of using compositions for forming microbial sealant drapes. In particular, the invention relates to the use of compositions of combinations of cyanoacrylates for the in situ formation of drapes that can be used in surgery to protect patients from surgical site infections. | 2010-05-06 |
| 20100112037 | S1P RECEPTOR AGONISTS FOR THE TREATMENT OF CEREBRAL MALARIA - Methods and compositions for treating, managing, and/or preventing cerebral malaria are disclosed. | 2010-05-06 |
| 20100112038 | METHODS OF TREATING NEUROLOGICAL CONDITIONS WITH HEMATOPOEITIC GROWTH FACTORS - The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor. | 2010-05-06 |
| 20100112039 | METHODS OF TREATING OVARIAN CANCER - Disclosed are methods of treating ovarian cancer (e.g., epithelial ovarian cancer) using lonafarnib, a taxane (e.g., paclitaxel or docetaxel) and a platinum coordinator complex (e.g., carboplatin, cisplatin or oxaliplatin). Also disclosed are methods of treating ovarian cancer (e.g. epithelial ovarian cancer) using lonafarnib, paclitaxel and carboplatin. Also disclosed are methods of treating ovarian cancer using lonafarnib in combination with a liposomal doxorubicin. | 2010-05-06 |
| 20100112040 | Preparation of Heavy Metal-Containing Nano-Liposomes and their Uses in Medical Therapy - Heavy metal-containing nano-liposome particles and their use in treating, for example, immune-related disorders, such as, cancer and inflammatory conditions, and metal deficiency-related diseases are described. The particles also can be used in diagnostic methods. The particles can contain gold, platinum or iron. | 2010-05-06 |
| 20100112041 | Endoxifen Compositions And Methods - The present invention provides compositions containing endoxifen, formulations and liposomes of endoxifen, methods of preparation of such agents and formulations, and use of such agents and formulations for the treatment of breast cancer and other breast diseases and diseases susceptible to endoxifen. In particular, the compositions of the present invention include liposomes, complexes, vesicles, emulsions, micelles and mixed micelles of endoxifen in which the compositions further contain any of a variety of neutral or charged lipids and desirably, cholesterol and cholesterol derivatives, sterols, Z- and E-guggulsterones, phospholipids, fatty acids, vitamin D, and vitamin E. The present invention also provides methods of preparing endoxifen. The present invention provides methods for treating and preventing breast cancer and other breast related diseases by administrating novel formulations or compositions comprising a therapeutically effective amount of endoxifen. | 2010-05-06 |
| 20100112042 | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics - Processes and compositions for liposomal delivery of therapeuticals prepared by contacting an aqueous solution of an active agent with a solution of liposome-forming components containing one or more DILA2 amino acid compounds or lipids in organic solvent to form an impinging stream. A protocol including flow rates, pH, and an incubation period are used to control formation of liposomal components for therapeutic applications. The impinging stream may be collected and incubated to prepare a liposomal formulation which encapsulates the active agent. The composition can be quenched with buffer and filtered by tangential flow and diafiltration and other means for finishing as a pharmaceutical composition. An efficiency for delivering a drug cargo is provided. Compositions can include a liposome containing one or more carrier particles, each carrier particle having an active agent and a peptide, wherein the ratio of the mass of the peptide plus the mass of the liposome to the mass of the active agent is less than about 15. | 2010-05-06 |
| 20100112043 | TRANSPULMONARY LIPOSOME FOR CONTROLLING DRUG ARRIVAL - An object of the present invention is to provide a liposome which is excellent in intrapulmonary delivery controllability of drugs or genes and is suited for pulmonary administration. | 2010-05-06 |
| 20100112044 | METHOD AND APPARATUS FOR ENCAPSULATING PHARMACEUTICAL AND NUTRICEUTICAL BIOACTIVES FOR INTESTINAL DELIVERY - A method for the encapsulation and subsequent delivery of a biologically, water or lipid soluble, active agent to the human intestinal mucosa. This biochemical pathway to drug delivery includes the steps of forming an aqueous emulsion of the pharmacological or nutriceutical agent, vegetable oil, gum and/or gum resin, absorbent factors, and a sugar; then converting the emulsion into a dry spherical particulate form, having lost its aqueous component; and then drying the resultant particulate to form acid and water insoluble intestinal absorbent biologically active beadlets. | 2010-05-06 |
| 20100112045 | SURFACE-TREATED MODAFINIL PARTICLES - The present invention is directed to solid oral dosage forms comprising surface-treated particles comprising modafinil particles and a hydrophilic treating agent, methods of making the same, and uses thereof. | 2010-05-06 |
| 20100112046 | FORMULATIONS OF SUBEROYLANILIDE HYDROXAMIC ACID AND METHODS FOR PRODUCING SAME - The present invention provides a pharmaceutical composition or crystalline composition with a specific dissolution profile, which comprises suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient. The present invention provides a process of producing said crystalline composition or pharmaceutical composition. The present invention also provides compositions with a specific particle size distribution. | 2010-05-06 |
| 20100112047 | OMEGA 3 FATTY ACID FORMULATIONS - The present invention provides highly purified omega-3 fatty acid formulations. Certain formulations provided herein have contain greater than 85% omega-3 fatty acids by weight. Certain other formulations provided herein contain EPA and DHA in a ratio of from about 4.01:1 to about 5:1. The invention also provides methods of using the dosage forms to treat a variety of cardiovascular, autoimmune, inflammatory, and central nervous system disorders by administering a formulation of the invention to a patient in need thereof. | 2010-05-06 |
| 20100112048 | Dosage Regimen and Medicament For Reducing Risk of Onset or Progression of Dementia by Administration of Specific Vitamins and Nsaid - The present invention relates to a synergistic combination for preventing the onset and/or progression of dementia or Alzheimer's disease in individuals at increased risk thereof for example because of family history, genetic factors, and/or environmental factors. This combination comprises synergistically effective amounts of vitamin C, vitamin E, DHA and at least one NSAID such as ibuprofen. | 2010-05-06 |
| 20100112049 | PHARMACEUTICAL COMPOSITION CONTAINING FENOFIBRATE AND METHOD FOR THE PREPARATION THEREOF - Pharmaceutical compositions comprising micronized fenofibrate, a surfactant and a binding cellulose derivative as a solubilization adjuvant, wherein said compositions contain an amount of fenofibrate greater than or equal to 60% by weight and methods of producing fenofibrate compositions. | 2010-05-06 |
| 20100112050 | Dosage Form For Insertion Into The Mouth - Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, particularly anti-migraine agents to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract. | 2010-05-06 |
| 20100112051 | TIANEPTINE SULFATE SALT FORMS AND METHODS OF MAKING AND USING THE SAME - Disclosed herein is a novel sulfate salt of tianeptine with improved properties. Also described herein are novel pharmaceutical compositions comprising tianeptine sulfate salt, methods of making, and related methods of treatment. | 2010-05-06 |
| 20100112052 | OSMOTIC TABLET WITH A COMPRESSED OUTER COATING - The present invention features a method of manufacturing an osmotic tablet including the steps of (i) compressing a tablet core including a first pharmaceutically active agent and a hydrophilic polymer; (ii) applying an osmotic coating to the outer surface of the tablet core to form a coated tablet, wherein the osmotic coating includes at least one opening exposing the tablet core; and (iii) compressing an immediate release coating onto the surface of the coated tablet, wherein the release coating includes a second pharmaceutically active agent. | 2010-05-06 |
| 20100112053 | GASTRIC RETENTION-TYPE SUSTAINED-RELEASE LEVODOPA PREPARATION - The present invention is to provide a levodopa preparation which is able to persistently release levodopa in the stomach, has a sufficient gastric residence time, is in an easily ingestible size and is able to be easily manufactured industrially with an object of maintaining a sustained concentration of levodopa in blood. It is a gastric retentive preparation for levodopa, characterized in that, the preparation contains a gastric resident layer showing a sufficient retentive property due to a high mechanical strength in the stomach and showing a good disintegrating property in an intestinal tract in addition to a drug releasing layer containing levodopa. | 2010-05-06 |
| 20100112054 | TABLETS AND DISCS WITH COMPARTMENTS WITH TWO OR MORE DRUGS FOR RELEASE AT CERTAIN INTERVALS AND WITH SPECIFIC RATES - The present invention includes systems, compositions and methods of making a multilayer modular release system, wherein the layers form a stack of active agent release layers, wherein the stack comprises a body and first and second ends and an impermeable coating surrounding the body of the stack, wherein the active agent is only release from the first, second or both the first and second ends of the stack by diffusion. | 2010-05-06 |
| 20100112055 | MICROPOROUS FILM AND PREPARATION AND USE THEREOF - The present invention is a new type of microporous film. The micoporous film can be applied to use as coating material of controlling drug release. The present invention also relates to a preparation of the microporous film. | 2010-05-06 |
| 20100112056 | IMMEDIATE RELEASE DOSAGE FORMS OF SODIUM OXYBATE - The present invention provides a pharmaceutical composition, presented as a solid unit dosage form adapted for oral administration of sodium oxybate. The preferred unit dosage form is a tablet comprising a relatively high weight-percentage of sodium oxybate, in combination with a relatively small weight-percentage of total excipients. This permits the tablets to contain/deliver a pharmaceutically effective amount, e.g., about 0.5-1.5 g of sodium oxybate in each tablet with a delivery profile similar to that of the liquid form. The tablets are bioequivalent to the liquid form. | 2010-05-06 |
| 20100112057 | MULTIFUNCTIONAL AND BIOLOGICALLY ACTIVE MATRICES FROM MULTICOMPONENT POLYMERIC SOLUTIONS - The present invention relates to a biologically active functionalized electrospun matrix to permit immobilization and long-term delivery of biologically active agents. In particular the invention relates to a functionalized polymer matrix comprising a matrix polymer, a compatibilizing polymer and a biomolecule or other small functioning molecule. In certain aspects the electrospun polymer fibers comprise at least one biologically active molecule functionalized with low molecular weight heparin. Examples of active molecules that may be used with the multicomponent polymer of the invention include, for example, a drug, a biopolymer, for example a growth factor, a protein, a peptide, a nucleotide, a polysaccharide, a biological macromolecule or the like. The invention is further directed to the formation of functionalized crosslinked matrices, such as hydrogels, that include at least one functionalized compatibilizing polymer capable of assembly. | 2010-05-06 |
| 20100112058 | HYDROGEL MASK PACK, METHOD OF PREPARING THE SAME, AND RELATED COMPOSITION - In a hydrogel mask pack having good skin-care effects, the hydrogel mask pack is formed by filling a frame with a composition for the hydrogel mask pack and immersing the frame in any one of an aqueous solution of a metal salt, alcohol or distilled water. The composition for the hydrogel mask pack is prepared by mixing an aqueous solution of fibroin and any one of alginate, cellulose or agar. The hydrogel mask pack may have superior moisturizing effects, skin-regenerative effects, mechanical strength and elasticity, and thus may be good enough to be used for a skin-care mask pack. | 2010-05-06 |
| 20100112059 | Methods, Systems and Devices for Administration of Chlorine Dioxide - Devices, compositions, systems and methods for the non-cytotoxic delivery of chlorine dioxide to a tissue. | 2010-05-06 |
| 20100112060 | FORMULATIONS OF ENTOMOPATHOGENIC FUNGI FOR INSECT CONTROL - The present invention describes insecticidal compositions comprising spores of entomopathogenic fungi suspended in oil in water emulsions comprising fatty acid salts, polyhydric alcohols, and additional emulsifiers. A method of producing such emulsions is presented. Methods for use of the compositions for preventing and controlling insect infestation in animals and natural areas, particularly tick infestations, are disclosed. | 2010-05-06 |
| 20100112061 | Monophosphates as Mutual Prodrugs of Muscarinic Receptor Antagonists and Beta-Agonists for the Treatment of COPD And Chronic Bronchitis - A mutual prodrug of a MRA and a (β-agonist for formulation for delivery by aerosolization to inhibit pulmonary bronchoconstriction is described. The mutual prodrug is preferably formulated in a small volume solution (10-500 μL) dissolved in a quarter normal saline having pH between 5.0 and 7.0 for the treatment of respiratory tract bronchoconstriction by an aerosol having mass median average diameter predominantly between 1 to 5μ, produced by nebulization or by dry powder inhaler. | 2010-05-06 |
| 20100112062 | KIDNEY STRUCTURES AND METHODS OF FORMING THE SAME - Provided herein are isolated populations of kidney cells harvested from differentiated cells of the kidney, wherein cells have been expanded in vitro, and methods of use thereof. The cells may be provided in a three dimensional matrix for culturing in vitro and/or implanting in vivo. Methods of seeding cells onto the matrix are also provided. | 2010-05-06 |
| 20100112063 | METHOD FOR PREPARING A HYDROGEL ADHESIVE HAVING EXTENDED GELATION TIME AND DECREASED DEGRADATION TIME - A method for extending the gelation time of an oxidized polysaccharide to react with a water-dispersible, multi-arm amine to form a hydrogel is disclosed. The extension of the gelation time is accomplished by using a chemical additive. The method also extends the time for the hydrogel to become tack-free, and may also be used to decrease the degradation time of the hydrogel. The chemical additive reacts with the functional groups of the oxidized polysaccharide or the water-dispersible, multi-arm amine, thereby reducing the number of groups available for crosslinking. The use of the resulting hydrogel for medical and veterinary applications is described. | 2010-05-06 |
| 20100112064 | TRANSDERMAL THERAPEUTIC SYSTEM COMPRISING ION PAIR MICRORESERVOIRS - The invention relates to a transdermal therapeutic system which comprises a back layer that is impermeable to the active substance, and a peelable protective layer that is impermeable to the active substance and at least one matrix layer consisting of polysiloxanes and/or polysiloxane derivatives and containing micro-reservoirs. Said micro-reservoirs contain at least one ion pair from a pharmacologically active substance and an additive and either the active substance is nucleophilic and the additive is electrophilic or the active substance is electrophilic and the additive is nucleophilic. | 2010-05-06 |
| 20100112065 | Therapeutic ultrasound gel - The therapeutic ultrasound gel is a composition that lubricates the abdomen for ultrasound scanning, that enhances the transmission of sound waves during ultrasound diagnostic imaging, and that has beneficial therapeutic effects in preventing the formation of stretch marks. The composition contains effective amounts of | 2010-05-06 |
| 20100112066 | Prostaglandin fat emulsion, method for producing the same, method for stabilizing the same, and emulsifying agent - A fat emulsion comprises a prostaglandin as an active ingredient, the fat emulsion comprising a phospholipid that comprises phosphatidylcholine (PC) and phosphatidylglycerol (PG) and has a ratio of PC to PG (PC:PG) of 85:15 to 99.7:0.3. | 2010-05-06 |
| 20100112067 | Compositions and methods for biological remodeling with frozen particle compositions - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 2010-05-06 |
| 20100112068 | Compositions and methods for biological remodeling with frozen particle compositions - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 2010-05-06 |
| 20100112069 | Flowable Carrier Matrix - A carrier matrix may be delivered to a target position within a patient in a minimally invasive manner by first cutting a collagen sponge sheet into a plurality of relatively small pieces. These pieces are sized so that, when wet, they are capable of flowing through a cannula and/or reduced-diameter syringe tip. The pieces are placed into a syringe and wetted, say with a morphogenic solution, and optionally mixed with a bulking material, which is similarly sized to fit through the cannula. The thoroughly mixed and wetted product forms a viscous aggregate which may then be injected into the patient at the target site. | 2010-05-06 |
| 20100112070 | Composition and dosage form comprising a particle formulation and suspending vehicle - A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent. | 2010-05-06 |
| 20100112071 | POLYPEPTIDES AND POLYNUCLEOTIDES FOR ENHANCING IMMUNE REACTIVITY TO HER-2 PROTEIN - Compositions for stimulating the immune system and for treating malignancies associated with overexpression of the HER-2 protein are provided. Such compositions include immunogenic epitopes of the HER-2 proteins and chimeric and multivalent peptides which comprise such epitopes. The present invention also relates to polynucleotides which encode the chimeric peptides. Also provided are pharmaceutical compositions comprising such immunogenic compositions. Methods for stimulating an immune response to HER-2 protein are provided. Methods for treating breast cancer, ovarian cancer, prostate cancer, colon cancer and lung cancer are provided. | 2010-05-06 |
| 20100112072 | Controllable Virus/Protein Assemblies and Methods of Making the Same - Methods of forming a bionanocomposite defining a shell and a core are generally provided along with the bionanocomposites themselves. The method includes non-covalently attaching biomacromolecules about a polymeric core such that the biomacromolecules cover at least about at least about 50% of the surface area of the polymeric core to form a shell. The polymeric core includes a polymer having pyridine functional groups. In one particular embodiment, the biomacromolecules can be attached to the polymeric core by combining an organic solution containing the polymer in an organic solvent with an aqueous solution containing the biomacromolecules to form an emulsion, mixing the emulsion, and removing the organic solvent. | 2010-05-06 |
| 20100112073 | Water-Soluble Nanoparticles Containing Water-Insoluble Compounds - Nanoparticles with entrapped, nonpolar compounds are disclosed, and a method for their synthesis. The nanoparticles are readily dissolved or dispersed in water. For example, the entrapped nonpolar compounds may include pharmaceutically-active compounds, or natural colorants. The nanoparticles have a nonpolar compound core, an intermediate surfactant layer, and an outer crosslinked polymeric protective layer. In a prototype example, alginic acid nanoparticles were prepared with beta-carotene entrapped in the core, with lecithin as the intermediate surfactant layer. In an alternative embodiment, a layer-by-layer assembly technique may be used to entrap the colorant within nanoparticles. | 2010-05-06 |
| 20100112074 | SILICONE MICROPARTICLES COMPRISING SILICONE ELASTOMER SPHERICAL MICROPARTICLES COATED WITH POLYORGANOSILSESQUIOXANE, AND METHOD OF PRODUCING SAME - Provided are silicone microparticles including 100 parts by mass of silicone elastomer spherical microparticles having a volume average particle diameter within a range from 0.1 to 100 μm, and 0.5 to 25 parts by mass of a polyorganosilsesquioxane that coats the surface of the silicone elastomer spherical microparticles, in which the silicone elastomer is capable of absorbing not less than 200 parts by mass of a polymethylsiloxane having a viscosity at 25° C. of not more than 10 mm | 2010-05-06 |
| 20100112075 | COMPOSITIONS OF MICROPARTICLES AND GRANULES FOR ORAL CONTROLLED RELEASE OF SUBSTANCES FOR VETERINARY USE - Microparticles or granules intended for use in the zootechnical field, constituted by a core which contains a substance having a pharmacological action, a food supplement or a diagnostic medium, intimately mixed or adsorbed with a hydrated silicate of magnesium, aluminum, calcium and sodium (smectite, montmorillonite or bentonite); the core is coated with a double fatty layer constituted by two fats or waxes, of which the one having the highest melting point constitutes the inner layer while the one having the lowest melting point is arranged so as to form the outer layer. The ability to control release effectively and accordingly reduce rumen degradation of active substances which contain a cationic or an anionic chemical function, such as for example choline chloride lysine hydrochloride, calcium chloride, citric acid, ascorbic acid or nicotinic acid is determined by the synergistic action of two phenomena: an interaction between the active substance and the other component of the core, and the barrier effect of the double fat layer. Taken individually, the two phenomena are unable to apply effective control over the release of the active substance. | 2010-05-06 |
| 20100112076 | Gellan-Gum Nanoparticles and Methods of Making and Using the Same - Compositions containing a reaction product of gellan gum and polyethylene glycol are disclosed. Methods of making controlled-release gellan gum nanoparticles and methods of using controlled-release gellan gum nanoparticles are also disclosed. | 2010-05-06 |
| 20100112077 | NANOPARTICLES OF PACLITAXEL AND ALBUMIN IN COMBINATION WITH BEVACIZUMAB AGAINST CANCER - The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents (such as an anti-VEGF antibody), or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime. | 2010-05-06 |
| 20100112078 | POLYMER PARTICLES BASED VACCINE - The present invention provides a vaccine composition comprising an effective amount of antigen or a nucleic acid encoding antigen, encapsulated in polymeric particles, wherein said polymeric particles comprises nanoparticles, microparticles or combinations thereof, wherein surprisingly the nanoparticle induces cellular response and the microparticle induces humoral response. The invention further provides a method of inducing cellular and/or humoral immune response. | 2010-05-06 |
| 20100112079 | Thyroid Hormone Analogs and Methods of Use - Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of thyroid hormone, or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed. | 2010-05-06 |
| 20100112080 | MULTIMERIC Fc RECEPTOR POLYPEPTIDES INCLUDING A MODIFIED Fc DOMAIN - A soluble multimeric polypeptide or protein is disclosed that is able to inhibit interaction of leukocyte Fcγ receptors (FcγR) and immunoglobulin G (IgG). The protein or polypeptide comprises two or more Fc binding regions linked in a head to tail arrangement, at least one of which is derived from an FcγR type receptor, and an Fc domain of an immunoglobulin which has been modified to reduce or prevent binding to the said Fc binding regions and/or to alter effector function. Also described are polynucleotide molecules encoding the polypeptide or protein and the use thereof in methods of treating a subject for an immune-complex (IC)-mediated inflammatory disease. | 2010-05-06 |
| 20100112081 | USE OF PLATELET RICH PLASMA COMPOSITION IN THE TREATMENT OF CARDIAC CONDUCTION ABNORMALITIES - Methods and kits for treating a cardiac arrhythmia using a platelet rich plasma (PRP) composition are provided. Any type of arrhythmia may be treated using the PRP composition. The PRP composition may comprise PRP developed using blood collected from a patient suffering the cardiac arrhythmia. The PRP composition may be buffered to a physiological pH and may include one or more anti-arrhythmic agents, anti-coagulants, or other drugs. The PRP composition may be delivered using a nebulizer, minimally invasively, or surgically. In some embodiments, the PRP composition may be coated on one or more medical devices. The PRP composition may be delivered to an identified portion of the electrical conduction system of the heart affected and/or causing the arrhythmia to occur. | 2010-05-06 |
| 20100112082 | Determining and Reducing Immunoresistance to a Botulinum Toxin Therapy Using Botulinum Toxin B Peptides - The present invention provides BoNT/B peptides, BoNT/B peptide compositions, tolerogizing compositions, immune response inducing compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of treating immunoresistance to botulinum toxin therapy in an individual, methods of reducing anti-botulinum toxin antibodies in an individual and methods of inducing a BoNT/B immune response an individual. | 2010-05-06 |
| 20100112083 | PHARMACEUTICAL PRODUCT FOR MODULATING BONE FORMATION, PROCESS FOR MODULATING BONE FORMATION - A pharmaceutical product and a process for bone regeneration and neoformation, which uses sirtuin modulators such as resveratrol and/or trans-resveratrol resulting in the substantial acceleration in the process of integration of biomaterials to the body, substantially shortening the recovery period of the injured or lost organ. | 2010-05-06 |
| 20100112084 | METHOD AND APPARATUS FOR INCREASING ADIPOSE VASCULAR FRACTION - A method and device for processing mammalian adipose tissue such that the vascular rich fraction is separated from the vascular poor fraction, Mammalian adipose tissue in the form of morselated surgical biopsies and/or lipoaspirate from liposuction is placed within a novel syringe attached to a detection device measuring either color, light saturation, infra-red light, heme, iron or oxygen saturation. This process involves no label and minimal manipulation and handling of the tissue. This process and device may also be used intra-operatively under sterile conditions for immediate use within the same individual receiving liposuction or surgery. | 2010-05-06 |
| 20100112085 | AGENT FOR STIMULATING LYMPHATIC DRAINAGE, METHOD FOR OBTAINMENT THE AGENT, AND METHOD FOR USING/ADMINISTERING THE AGENT - A lymphatic drainage stimulant is disclosed, which is produced by -providing a body of drinking water that meets predetermined sanitary requirements, and -treating the water body with a baro-membranous system. The treating preferably includes passing the water through a semi-permeable reverse-osmosis membrane made with a hole size 0.0001-0.005 μm, so that the water acquires the following parameters: a redox potential ranging from +200 to +343 mV, total mineralization ranging from 25 to 130 mg/L, and pH index ranging from 6.9 to 8.3. An optional method additionally includes saturating the water with macro- and microelements. The stimulant can be administered for medical treatment of patients with chronic skin diseases, non-oncological diseases of gastrointestinal tract, and chronic obstructive bronchitis. In such case, the stimulant is taken 30-40 minutes before and 2-2.5 hours after each meal, altogether 1.5-2.5 L a day, and the first dose is taken during the morning fast. | 2010-05-06 |
| 20100112086 | ELECTROLYTICALLY REDUCED WATER, HOT WATER FOR BATHING, AND METHOD FOR SUPPRESSION OF LUMPY FAT - An electrolytically reduced water which consists of an alkali ion water prepared by ion exchange and has a dissolved hydrogen concentration of 0.20 ppm or above, an oxidation-reduction potential of −150 mV to −500 mV, and a hydrogen ion component of pH6.5-10.5 and which is quantitatively specified in the reducing power capable of inhibiting the oxidative deterioration of fat in the cutis through the elimination of active oxygen due to the characteristics of hydrogen, the oxidation-reduction potential characteristics of high reducing action, and alkaline characteristics and can activate the skin to inhibit the oxidative deterioration and suppress lumpy fat (cellulite). | 2010-05-06 |
| 20100112087 | OXYGEN-GENERATING COMPOSITIONS FOR ENHANCING CELL AND TISSUE SURVIVAL IN VIVO - A method of treating hypoxic tissue such as wound tissue comprises contacting a composition to the hypoxic tissue in a hypoxia-treatment effective amount, the composition comprising a biodegradable polymer and an inorganic peroxide incorporated into the polymer. | 2010-05-06 |
| 20100112088 | MATERIALS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS - The subject invention pertains to materials and methods for the prevention and treatment of disease conditions associated with oxidative stress or a compromised reducing environment, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Therapeutic compositions of the invention include compositions that can neutralize hydrogen peroxide, such as reducing agents and oxidizing agents. In one embodiment, a therapeutic composition of the invention comprises a reducing agent such as sodium thiosulfate. Therapeutic compositions of the invention can optionally include compounds with antibacterial activity, compositions that inhibit bacterial adherence to cells and tissue, compositions that inhibits epithelial lipid peroxidation, compositions that add viscosity to a solution, compositions that inhibit most cells, and/or compositions that help to seal or repair tight junctions between cells of the colonic epithelium of the gastrointestinal tract. Methods of the invention include administration of compounds or compositions of the invention. In one embodiment, compounds or compositions of the invention are rectally instilled in a patient. | 2010-05-06 |
| 20100112089 | PEPTIDE COMPOUND AND USE THEREOF - The present invention provides a method for the prophylaxis or treatment of cancer in a mammal, comprising administering a therapeutically effective amount of CBP501, a prodrug thereof or a pharmaceutically acceptable salt thereof to the mammal, wherein CBP501, a prodrug thereof or a pharmaceutically acceptable salt thereof is administered simultaneously with or before administration of a nucleic acid damaging agent. | 2010-05-06 |
| 20100112090 | NITROGENATED FUSED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE SAME FOR MEDICAL PURPOSES - [Purpose] The present invention provides compounds useful as agents for the prevention or treatment of a sex hormone-dependent disease or the like. | 2010-05-06 |
| 20100112091 | USE OF RAMOPLANIN TO TREAT DISEASES ASSOCIATED WITH THE USE OF ANTIBIOTICS - The invention features a method of treating or preventing a disease associated with the use of antibiotics in a patient in need thereof by administering to the patient ramoplanin in an amount and for a duration effective to treat said disease. The disease may be caused, for example, by the presence of a bacterium such as enterotoxin producing strains of | 2010-05-06 |
| 20100112092 | ANTIMICROBIAL SOLUTIONS CONTAINING DICHLORINE MONOXIDE AND METHODS OF MAKING AND USING THE SAME - Methods and products are provided for treating a wound or infection in a mammal or disinfecting a surface with a hypochlorous acid solution that has been activated by a catalyst. Additionally provided is a process for preparing an antimicrobial product that produces an activated hypochlorous acid solution for use as an antimicrobial. | 2010-05-06 |
| 20100112093 | Compositions and methods for therapeutic delivery with frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 2010-05-06 |
| 20100112094 | METHOD FOR PRODUCING PEROXYMONOSULFURIC ACID AND APPARATUS FOR CONTINUOUSLY PRODUCING PEROXYMONOSULFURIC ACID - The invention provides a method for producing a peroxymonosulfuric acid solution with high stability, including the steps of mixing 35 mass % or more of hydrogen peroxide and 70 mass % or more of sulfuric acid to react them, cooling the reaction solution to 80° C. or lower within five minutes after initiation of the mixing step, and diluting the reaction solution with water four times or more as much as the reaction solution by mass. | 2010-05-06 |
| 20100112095 | BIFUNCTIONAL MATERIAL FOR NITRIC OXIDE STORAGE AND PRODUCTION AND USE THEREOF IN THERAPY - The present invention relates to a bifunctional material which comprises copper and which is capable of storing nitric oxide (NO), as well as catalytically producing nitric oxide from a suitable precursor. The material typically includes a zeolite and the copper may be part of or separate from the zeolite. In this manner the material may include a single bifunctional material; that is, a material which is capable of both storing NO and catalytically producing NO, such as Cu-MFI or Cu—X. Alternatively the material may include at least two components, a first component to store NO, such as a zeolite Zn-LTA, and a further component including Cu(I), such as Cu | 2010-05-06 |
| 20100112096 | DRY EXTRACTS OF PELARGONIUM SIDOIDES AND PELARGONIUM RENIFORME - The invention relates to production methods for obtaining dry extracts from | 2010-05-06 |
| 20100112097 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CANCER AND HEALTH FOOD CONTAINING THE SAME FOR PREVENTING AND TREATING CANCER - A pharmaceutical composition for treating and preventing cancer, and health food for ameliorating and preventing cancer containing the pharmaceutical composition are provided. The pharmaceutical composition includes | 2010-05-06 |
| 20100112098 | EFFECTS OF A DECAFFEINATED GREEN COFFEE EXTRACT ON BODY WEIGHT CONTROL BY REGULATION OF GLUCOSE METABOLISM - A method of controlling body weight in humans by administering an amount of decaffeinated green coffee extract effective to treat a subject. A preferred green coffee extract contains a ratio of 5-caffeoylquinic acid (5-CQA) and total chlorogenic acids (tCGA) (5-CQA/tCGA) of between about 0.2 and 0.3. More preferably, the concentration of tCGA is greater than about 45% and the concentration of 5-CQA is less than about 10%. A preferred method of administration consists of administering between about 200 mg and about 1,000 mg per day, more preferably administering about 400 mg per day. | 2010-05-06 |
| 20100112099 | PHYTOCHEMICAL COMPOSITIONS AND METHODS FOR ACTIVATING AMP-KINASE - The present invention relates to AMPK activation utilizing phytochemicals, natural plant extracts and combinations. Disclosed are methods, compounds, and compositions comprising drugs, medical foods, and dietary supplements for the prevention and treatment of metabolic disorders, in particular obesity, weight gain, insulin resistance syndromes, diabetes, fasting hyperlipidemia and osteoarthritis. More specifically, the invention relates to pharmaceutical therapeutic methods and compositions utilizing phytochemicals, natural plant extracts and combinations to modify myocyte, hepatocyte, adipocyte, cardiac or pancreatic physiology through activation of AMPK. | 2010-05-06 |
| 20100112100 | COMPOSITIONS COMPRISING A C-GLYCOSIDE COMPOUND - The present invention relates, in particular, to:
| 2010-05-06 |
| 20100112101 | BIO-AVAILABILITY/BIO-EFFICACY ENHANCING ACTIVITY OF STEVIA REBAUDIANA AND EXTRACTS AND FRACTIONS AND COMPOUNDS THEREOF - The present invention discloses bio-efficacy and bio-availability enhancing composition comprising, an effective amount of | 2010-05-06 |
| 20100112102 | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF BENIGH PROSTATE HYPERPLASIA, PROSTATITIS, IMPOTENCE, INFERTILITY AND PROSTATE CANCER AND A METHOD FOR THE USE THEREOF - Therapeutic compositions are proposed for treating and preventing benign prostatic hyperplasia, prostatitis, impotency, infertility and prostate cancer and to a method for the use thereof. They are based on dextrorotary or levogeratory or racemic camphor in the form of a fatty-oil-dimexide emulsion, an oil-aqueous emulsion, or suppositories, the camphor quantity being of 0.1-15.0% by volume. The compositions are rectally administrable once a day by course of therapy up to 20 days every year. They increase the resistance of tissue colloids, activate the erection center of the parasympathetic nervous system, exhibit M- and H-cholinolytic action, produce tonic action on the ejaculation center, normalize the capillary and venule tonus, stimulate vasomotor centers of the spinal chord, enhance the synthesis of macroergic phosphates, inhibit ATP-acid splitting in the hypoxia conditions and exhibit analgesic, bactericidal and fibrinolytic effect, etc. The compositions and method enable carrying out the preventive treatment of the above-listed disease. | 2010-05-06 |
| 20100112103 | BURN TREATMENT COMPOSITION AND METHOD - The invention is directed to a method for treating topical burns with compositions comprising a silicone containing compound, a Vitamin E compound and a local anesthetic. | 2010-05-06 |
| 20100112104 | COSMETIC PREPARATIONS DESIGNED TO REDUCE UNSIGHTLY CELLULITE - The invention relates to a new derivative of aryldimethylpyrazolone of formula (I) which is effective in reducing unsightly cellulite, and compositions containing it. | 2010-05-06 |
| 20100112105 | Antimicrobial efficacy of aframomum Melegueta extract against propionibacterium acnes - The use of compositions containing one or more phytochemicals such as gingerols, paradols, and mixtures thereof for aiding in the control, reduction or elimination of | 2010-05-06 |
| 20100112106 | SYNERGISTIC HERBAL OPHTHALMIC FORMULATION FOR LOWERING THE INTRA OCULAR PRESSURE IN CASE OF GLAUCOMA - The present invention relates to a synergistic herbal composition for lowering the intra ocular pressure in different types of glaucoma and process for the preparation of the same in pharmaceutically acceptable dosage forms. | 2010-05-06 |
| 20100112107 | PLANT EXTRACT COMPOSITIONS FOR AFFECTING SLEEP - A composition for affecting physiological sleep disorders comprising a therapeutically effective amount of Baiziren extract or any of its derivatives, and a pharmaceutically acceptable carrier. The composition may additionally comprise a therapeutically effective amount of at least one of a Suanzaoren extract and a Yuanzhi extract, or mixtures thereof. | 2010-05-06 |
| 20100112108 | Extracts of Aristolochia Longa pomer and uses thereof - Methods of extracting from a part of a variety of the species | 2010-05-06 |
| 20100112109 | CONTAINER MOLD EXCHANGING APPARATUS - A container mold exchanging apparatus includes: a container support body which supports the jacket of the container from which the lower sidewall mold is separated; a gripping mechanism which includes upper and lower gripping members and grips each tread mold so as to be interposed between the upper and lower gripping members in the vertical direction; first and second driving mechanisms which respectively elevate the upper and lower gripping members; a third driving mechanism which expands or contracts the upper and lower gripping members in the radial direction of the container; and a fourth driving mechanism which moves the gripping mechanism along the axis of the container relative to the container support body. | 2010-05-06 |
| 20100112110 | APPARATUS FOR TRANSFERRING DOSES - An apparatus for transferring doses includes a forming arrangement for forming an object from a dose of flowable material and a transferring arrangement for transferring the dose to the forming arrangement. The transferring arrangement has a recess for receiving the dose. The recess is provided with a rolling arrangement for guiding the dose inside the transferring arrangement. | 2010-05-06 |
| 20100112111 | DEVICE FOR THE PRODUCTION OF MULTI-LAYER TUBES - A device for the production of multi-layer tubes (A), in particular foam core tubes, with an extruder arrangement ( | 2010-05-06 |
| 20100112112 | DEVICE FOR MANUFACTURING A RUBBER STRIP | 2010-05-06 |
| 20100112113 | MOLD FASTENING DEVICE AND METHOD OF CONTROLLING THE MOLD FASTENING DEVICE - A mold fastening device has a fixed die plate, a rear plate, a movable die plate that can move back and forth, a toggle mechanism, and a drive motor that drives a cross-head. The position where the cross-head should be stopped is associated with the rate at which to accelerate the cross-head from that position or the rate at which to decelerate the cross-head to that position. The cross-head is operated at an acceleration that corresponds to that position. The drive motor is thereby driven at a constant output torque, regardless of the position of the movable die plate. Further, the time for opening and closing metal molds can be shortened. | 2010-05-06 |
| 20100112114 | HYDROGEL PROCESSING - Disclosed are methods and apparatus for hydrating ophthalmic lenses and leaching excess materials from the ophthalmic lenses. The methods include the steps of exposing contact lenses with a hydration solution comprising about 30 to 70 percent isopropyl alcohol and water. In some embodiments, the hydration solution is maintained at an elevated temperature. Exposure to a first hydration solution causes the ophthalmic lenses to swell to a size larger than their functional size, and exposure to a second ophthalmic solution causes the lenses to shrink back to a functional size. | 2010-05-06 |
| 20100112115 | MOLD FOR PRODUCING A SILICA CRUCIBLE - A mold for the production of a silica crucible by heat-fusing silica or quartz powder attached onto an inner wall of a rotating mold, wherein a ring-shaped heat insulating barrier material having a specified inner diameter is disposed on an inner peripheral wall of an upper opening portion of the mold corresponding to an upper region of the silica crucible. | 2010-05-06 |
| 20100112116 | Double-Sided Nano-Imprint Lithography System - A nano-imprint lithography system is described for patterning first and second substrates, the system includes a translation stage constructed to alternatively place substrate chucks in position with respect to a nano-imprint mold assembly such that the nano-imprint mold assembly may imprint a pattern on one of the substrates, while concurrently obtaining a desired spatial relationship for the remaining substrate. | 2010-05-06 |
| 20100112117 | REUSABLE INFUSION BAG - A reusable apparatus and method for forming a composite part through vacuum assisted resin transfer molding (VARTM). The reusable apparatus may be configured to vacuum seal a curable material, such as composite material, against a tool and disperse a permeating substance such as liquid resin through the curable material. The reusable apparatus may comprise a sheet of material such as rubber having a plurality of surface deviations facing the curable material and the tool. The surface deviations may provide paths for evenly distributed air flow as air is evacuated from between the sheet of material and the tool. Additionally, the surface deviations may allow the permeating substance to be evenly dispersed throughout the curable material. A vacuum outlet of the tool may be positioned between two sealing apparatuses to provide continuous vacuum suction proximate a perimeter of the sheet of material to prevent air from leaking in. | 2010-05-06 |
